OncoMatch/Clinical Trials/NCT06104488
A Study of Avutometinib for People With Solid Tumor Cancers
Is NCT06104488 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Avutometinib for refractory cancer.
Treatment: Avutometinib — The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Tumor Agnostic
Glioblastoma
Neuroblastoma
Biomarker criteria
Required: BRAF fusion
activating MAP kinase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations
Required: BRAF mutation
activating MAP kinase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations
Required: ARAF fusion
activating MAP kinase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations
Required: ARAF mutation
activating MAP kinase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations
Required: RAF1 fusion
activating MAP kinase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations
Required: RAF1 mutation
activating MAP kinase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations
Required: KRAS alteration
KRAS/NRAS/HRAS alterations
Required: NRAS alteration
KRAS/NRAS/HRAS alterations
Required: HRAS alteration
KRAS/NRAS/HRAS alterations
Required: PTPN11 mutation
PTPN11 or SOS1/2 mutations
Required: SOS1 mutation
PTPN11 or SOS1/2 mutations
Required: SOS2 mutation
PTPN11 or SOS1/2 mutations
Required: NF1 loss of function alteration
loss of function alterations in NF1
Required: NF1 germline alteration
Participants with a clinical or molecularly confirmed (germline alteration positive) diagnosis of NF1
Required: NF2 pathogenic mutation
Only patients with pathogenic and likely pathogenic variants in NF2 will be permitted to enroll
Demographics
Prior therapy
Lab requirements
Blood counts
platelets ≥100,000/mm3; ANC ≥ 1000/mm3; no transfusions or growth factor support for ≥ 7 days prior to demonstrating adequate function (except for malignant bone marrow infiltration)
Kidney function
Maximum serum creatinine for age/gender (see table); or 24h CrCl or GFR ≥ 85 ml/min
Liver function
total bilirubin ≤ 1.5 × ULN (Gilbert syndrome < 3.0 mg/dL); ALT/AST ≤ 2.5 × ULN (or < 5x ULN with liver metastases); albumin ≥ 3.0 g/dL
Adequate hepatic, renal, and hematologic function as defined in protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Healthcare of Atlanta (Data Collection Only) · Atlanta, Georgia
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06104488 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require BRAF?
Yes, BRAF fusion is a required biomarker for enrollment.
Does this trial require BRAF?
Yes, BRAF mutation is a required biomarker for enrollment.
Does this trial require ARAF?
Yes, ARAF fusion is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 30 years or younger and at least 3 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages